مباشر
FierceBiotechKurma closes €215M Europe-focused fund to spread across 20 biotechsFierceBiotechPfizer cans work on next-gen conjugate in cancer patientsThermo FisherThermo Fisher (TMO) Q1 2026 Earnings Transcript - The Motley FoolLonza NewsBanks kick off talks on Lone Star’s $1.75 billion Lonza unit debt - Bloomberg News - TradingViewPromega BlogThe Body Already KnowsLonza NewsBanks Kick Off Talks on Lone Star’s €1.5 Billion Lonza Unit Debt - Bloomberg.comThermo FisherThermo Fisher Scientific Q1 2026 Earnings Call: Complete Transcript - BenzingaThermo FisherThermo Fisher stock drops despite Q1 beat (update) (TMO:NYSE) - Seeking AlphaBioWorldAvacta Life Sciences patents FAP-activated camptothecin conjugatesBioWorldMabwell discloses new ADAM9-targeting ADCsBioWorldFosun Pharma discovers new PKMYT1 inhibitorsBioWorldChengdu Mfs Pharma synthesizes new compounds for pain
FierceBiotech ١٩ ديسمبر ٢٠٢٥

Boehringer walks away from Nxera's phase 2-ready schizophrenia program

Boehringer walks away from Nxera's phase 2-ready schizophrenia program

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.